Isomorphic Labs raises $5B Series C co-led by Greenoaks and Sequoia
Isomorphic Labs says it raised a $5 billion Series C, co-led by Greenoaks and Sequoia, to scale its drug-design platform.
Isomorphic Labs has raised a $5 billion Series C, co-led by Greenoaks and Sequoia. The company says the money will go toward scaling its drug-design platform and developing its therapeutic pipeline.
The announcement is general. It names the two uses of the money but does not say how the $5 billion will be split between building out the platform and advancing drug candidates.
What changed
Isomorphic Labs raised a $5 billion Series C, co-led by Greenoaks and Sequoia, to scale its drug-design platform.
Type: Business
Why it matters
The round shows investors funding AI drug discovery as a full pipeline business. That matters for pharmaceutical companies deciding whether to partner with it or with smaller tool vendors.
What you can do
If you work in pharma or biotech, review your AI drug-discovery partnerships in light of better-funded competitors.
How the story developed
This coverage adds that the funding is meant to advance candidates toward human trials.
Original source
We have no link to the original source for this story yet.
Further reporting
Where we saw it
Forward Future (Matthew Berman), Latent Space
AI wrote this summary from the sources listed, and nobody reviewed it individually before publication. Check the original source before you rely on it. How it works